News
International News
Education
Environment
Healthcare
Technology
Internet
Science
Social and Non-Profit
Local News
Politicsand Policy
Government
Politics
Local Government
International Policy
Businessand Economy
Economy
Finance
Financial Markets
Jobs and Labor
Company News
Industry News
Aerospace
Agriculture
Chemicals
Commodities
Construction and Engineering
Consumer Electronics
Defense
Energy
Nuclear Energy
Oil and Gas
Renewable Energy
Financial Services
Banking
Insurance
Fishing and Aquaculture
Manufacturing
Information Technology
Metals and Mining
Pharmaceuticals and Biotechnology
Real Estate
Professional and Business Services
Legal
Telecommunications
Tobacco
Retail
Transportation
Air Transportation
Maritime Transportation
Rail Transportation
Road Transportation
Utilities
Forestry and Wood Industry
Artsand Culture
Art
Books and Literature
Entertainment
Cinema
Media
Radio and Television
Music
Lifestyleand Leisure
Automotive
Home and Garden
Fashion and Luxury
Textile and Apparel
Food
Travel and Hospitality
Boating and Yachting
Sports
Baseball
Basketball
Boxing
Cricket
Cycling
Football (American)
Football (Australian)
Football (Soccer)
Golf
Hockey
Racing
Rugby
Sailing
Skiing and Winter Sports
Tennis
Volleyball
The security settings of your browser are blocking the execution of scripts.
To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.
If you have changed your browser's security settings, you can click here.
Geron Corporation
Statement of Changes in Beneficial Ownership (Form 4)
-5d
Initial Registration Statement for Employee Benefit Plan (Form S-8)
-6d
Outcomes of Imetelstat Therapy In Patients with Ring Sideroblast-Negative Lower-Risk Myelodysplastic Syndromes From The Pooled Imerge Study Populations
6/14
Outcomes with Imetelstat by Serum Erythropoietin Levels In Patients with Lower-Risk Myelodysplastic Syndromes Who Were Treatment Naive or Who Had Prior Treatment with Erythropoiesis-Stimulating Agents
Health-Related Quality of Life Outcomes In Patients with Lower-Risk Myelodysplastic Syndromes Treated with Imetelstat In the Imerge Trial
IMproveMF Update: Phase 1/1B Trial of Imetelstat + Ruxolitinib in Patients With Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis
6/13
Increased Duration Of Time Without Transfusion Reliance (TWITR) For Patients With Lower-Risk Myelodysplastic Syndromes Treated With Imetelstat Versus Placebo In the Imerge Trial
IMpactMF, Randomized, Open-Label, Phase 3 Trial of Imetelstat Versus Best Available Therapy In Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitors
IMpactMF, Randomized, Open-Label, Phase 3 Trial of Imetelstat Versus Best Available Therapy in Patients With Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitors
6/2